Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
Antimicrobial Proteins01:23

Antimicrobial Proteins

Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor.

Frontiers in immunology·2026
Same author

Hepatitis C Virus Can Induce Gene Expression Changes Associated with Hepatocarcinogenesis.

JHEP reports : innovation in hepatology·2026
Same author

Multi-omics profiling reveals divergent biology and liver microenvironment in HCC of metastatic and de novo origin.

Molecular cancer·2026
Same author

Whole-Genome Sequencing of Hepatitis B Virus Genotypes E and A in Zambia Reveals Limited Viral Diversity in HIV Coinfection.

Open forum infectious diseases·2025
Same author

The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.

Nature communications·2025
Same author

Human-correlated genetic models identify precision therapy for liver cancer.

Nature·2025
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Interferons and hepatitis C virus.

Markus H Heim1

  • 1University Hospital Basel, Switzerland. Markus.Heim@unibas.ch

Swiss Medical Weekly
|May 11, 2012
PubMed
Summary
This summary is machine-generated.

Interferon therapy for chronic hepatitis C can fail due to the patient's own activated interferon system. Genetic variations near the IFNλ3 gene (IL28B genotype) significantly impact hepatitis C virus clearance and treatment response.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Experiment Videos

Last Updated: May 22, 2026

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons
09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Area of Science:

  • Immunology
  • Virology
  • Genetics

Background:

  • Interferons are crucial for antiviral defense against hepatitis C virus (HCV).
  • Recombinant interferon alpha has been a primary treatment for chronic HCV for over two decades.
  • Mechanisms of non-response to interferon therapy are not fully understood.

Purpose of the Study:

  • To investigate factors influencing non-response to interferon-based therapies for chronic hepatitis C.
  • To explore the role of endogenous interferon system activation and genetic factors in treatment outcomes.
  • To understand the molecular links between IL28B genotype and antiviral immunity.

Main Methods:

  • Analysis of liver biopsies from chronic hepatitis C patients to assess endogenous interferon system activation.
  • Genome-wide association studies (GWAS) to identify genetic variants associated with HCV clearance and treatment response.
  • Review of current knowledge on interferon induction pathways (Toll-like receptor, RIG-I/MDA5) and signaling.

Main Results:

  • Spontaneous activation of the liver's endogenous interferon system prevents response to interferon therapy.
  • Genetic variants near the IFNλ3 gene (IL28B genotype) are strongly associated with spontaneous HCV clearance and treatment response.
  • Progress has been made in understanding interferon induction and signaling pathways.

Conclusions:

  • Endogenous interferon system activation is a key mechanism of non-response to interferon therapy in chronic hepatitis C.
  • The IL28B genotype is a significant predictor of HCV clearance and treatment success.
  • Further research into host-virus interactions and viral escape mechanisms is needed for vaccine development.